Clinical Study On Guilong Tongluo Capsule In The Treatment Of Diabetic Peripheral Neuropathy

ObjectiveTo observe the efficacy and safety of Guilong Tongluo Capsule in the treatment of distal symmetrical polyneuropathy(DSPN),and provide an objective basis for Guilong Tongluo Capsule in the treatment of diabetic peripheral neuropathy.Methods72 patients with qi and yin deficiency and collateral venous obstructive distal symmetrical polyneuropathy were selected as subjects.The patients were all patients with distal symmetrical polyneuropathy in the Department of Endocrinology,Yiling Hospital,Hebei Province,March 2017-2018.In this study,randomized digital table method was used to randomly divide patients into two groups: test group and control group.Group of 36 cases.The control group was treated with mecobalamin tablets,0.5 mg each time,3 times a day,orally,for routine treatment.On the basis of the treatment of the control group,the experimental group was added with Guilong Tongluo Capsules,4 capsules each time,3 times a day,orally.6 months is a course of treatment.The electromyogram,Toronto Clinical Score(TCSS)and total scores of TCM symptom groups were observed before and after treatment in72 patients.The therapeutic effect of Guilong Tongluo Capsule on diabetic peripheral neuropathy was evaluated after one course of treatment Result1.The total scores and curative effect of TCM symptoms: the scores of the experimental group before and after treatment were 10.42±1.32,5.44±2.72,and the scores of the control group before and after treatment were 10.94±1.33,6.94±3.21.After the end of the test period,the test group and the control group before and after treatment,the total scores of TCM symptoms decreased after treatment(P<0.05).Compared with the control group,the experimental group was superior to the control group(P<0.05).The total effective rate of the two groups was P=91.4%,P=71.4%,and the experimental group was superior to the control group(P<0.05).The clinical efficacy of the experimental group was better than that of the control group(P<0.05).2.Contrast of clinical indicators:before and after treatment,glycated hemoglobin(Hb A1c)test group was 7.70±0.58%,7.68±0.66%,and fast blood glucose(FBG)was 10.02±0.76mmol/l,10.09±1.00 mmol/l,2-ho ur postprand blood glucose(2h PBG)was 11.77±1.21mmol/l,11.50±1.10 m mol/l,and Hb A1 c before and after treatment was respectively7.67±0.60%,7.66±0.66%.FBG was 9.72±0.81mmol/l,9.73±0.82mmol/l respectivel y.2h PBG was respectively 11.38±1.43mmol/l,11.39±1.06mmol/l.The tot al sural nerve amplitude test group before andafter treatment was resp ectively 2.98± 1.64 mv,3.86 ± 1.33 mv.The control group were respecti vely 2.99 ± 1.85 mv,3.17 ± 1.88 mv.Before and after treatment,the tot al nerve conduction velocity test group was respectively 38.81±7.98m/s and 40.35±7.68m/s,and the control group was 38.66±6.83m/s and 40.65±7.05m/s respectively.Thesural nerve amplitude test before and af ter treatment was respectively 6.16± 2.56 uv and 7.26± 2.70 uv,and the control group was 5.77± 2.70 uv and 6.18± 3.04 uv respectively.The sur al nerve conductionvelocity test group before and after treatment was39.64±7.65 m/s and46.62±8.10 m/s respectively.The control group were 40.85±6.37m/s and 42.85±7.28m/s respectively.The TCSSscore test gro up before and after treatment was respectively 10.89±2.58and7.34±2.62,and the control group was 11.03±2.37 and 8.71±2.97 respectively.After the end of the trial period,the Hb A1 c,FBG and PBG of the two gro ups were with no significant difference(P>0.05)compared beforeand af ter the treatment in the experimental group and the control group.Com mon peroneal nerve and sural nerve amplitude increased(P<0.05).Co mmon peroneal nerve conduction velocity increased(P<0.05).Sural nerve conduction velocity increased(P<0.05).TCSS decreased(P<0.05).Ther e was no significant difference in Hb A1 c between thetwo groups after treatment(P>0.05).After treatment,the amplitudeand conduction velocity of the sural nerve,the amplitude andconduction velocity of the commo n peroneal nerve,and the TCSS integralcomparison between the two gr oups showed that the experimental group was superior to the control group(P<0.05).ConclusionGuilong Tongluo Capsule can effectively improve the nerve conduction velocity and amplitude of patients with distal symmetric multiple diabetic peripheral neuropathy,reduce TCSS score and improve clinical symptoms.It is indicated that Guilong Tongluo Capsule is safe and effective in the treatment of diabetic peripheral neuropathy.